Tolerance of efavirenz in children

AIDS

Volumn 15, Issue 2, 2001, Pages 241-243

  Teglas, J P ^a   Quartier, P ^a   Treluyer, J M ^a   Burgard, M ^a   Gregoire, V ^a   Blanche, S ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Children; Efavirenz; HIV; Non Nucleoside reverse transcriptase inhibitor; Treatment

Indexed keywords

DIDANOSINE; EFAVIRENZ; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ADOLESCENT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERANCE; DRUG WITHDRAWAL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LYMPHOCYTE COUNT; NEUROTOXICITY; PRIORITY JOURNAL; SCHOOL CHILD; SKIN MANIFESTATION; VERTIGO;

ADOLESCENT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CHILD; HIV INFECTIONS; HUMANS; OXAZINES; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD;

EID: 0035951441     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200101260-00014     Document Type: Article

References (6)

1. Clinical uses of non nucleoside reverse transcriptase inhibitors
2. Combination treatment with zidovudine, didanosine and nevirapine in infants with human immunodeficiency virus type 1 infection
3. Combination therapy with efavirenz, nelfinavir and nucleoside reverse transcriptase inhibitors in children infected with human immunodeficiency virus type 1
4. 1994 revised classification system for HIV infection in children less than 13 years of age
5. Acquired immune deficiency syndrome (AIDS) interim proposals for a WHO staging system for HIV-1 infection and disease